Seshiru Nakazawa, MD, PhD, on NSCLC and Point Mutations as de Novo Oncogenic Drivers

October 04, 2023 By The ASCO Post Staff

Seshiru Nakazawa, MD, PhD, of Dana-Farber Cancer Institute, discusses activating the MET tyrosine kinase domain mutation, which has been identified as the sole oncogenic mutation in a small but significant subset of patients with non–small cell lung cancer (NSCLC). According to Dr. Nakazawa’s findings, this mutation is potentially targetable with currently available MET tyrosine kinase inhibitors.

Related Content